Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Department of Clinical Laboratory, Osaka International Cancer Institute, Osaka, Japan.
Cancer Med. 2023 Apr;12(7):7888-7892. doi: 10.1002/cam4.5563. Epub 2023 Jan 11.
Appropriate sample selection with a tumor fraction ≥20% without necrosis contamination is required for successful cancer genomic profiling (CGP). Rapid on-site evaluation (ROSE) is performed to assess adequate sampling.
This retrospective study included 54 patients who underwent CGP using liver tumor biopsy specimen with ROSE.
The sampling success rate (98.1%) was higher than the previously reported 77.5%-88.9%. ROSE was performed once in 51 patients and twice in three patients; for those undergoing ROSE twice, the first ROSE was negative for malignancy, or showed few tumor cells with necrotic cell contamination, while the second ROSE obtained from another location showed abundant malignant cells. In these patients, the CGP was successful using the second specimen, though the first sample did not meet the required criteria for CGP test.
Performing ROSE during liver tumor biopsy may be useful for CGP test sampling because ROSE prevents sampling errors and contributes to adequate sampling.
成功进行癌症基因组分析(CGP)需要选择肿瘤占比≥20%且无坏死污染的合适样本。快速现场评估(ROSE)用于评估充分的采样。
本回顾性研究纳入了 54 例使用 ROSE 进行肝肿瘤活检标本进行 CGP 的患者。
采样成功率(98.1%)高于之前报道的 77.5%-88.9%。51 例患者进行了一次 ROSE,3 例患者进行了两次 ROSE;对于进行了两次 ROSE 的患者,第一次 ROSE 为阴性,无恶性肿瘤细胞,或仅显示少数肿瘤细胞伴有坏死细胞污染,而第二次 ROSE 取自另一个部位,显示出大量恶性细胞。在这些患者中,使用第二个标本进行 CGP 是成功的,尽管第一个样本不符合 CGP 测试的要求标准。
在肝肿瘤活检期间进行 ROSE 可能有助于 CGP 测试采样,因为 ROSE 可以防止采样错误并有助于充分采样。